timolol ophthalmic solution

DRUG4 trials

Sponsors

Allergan, Santen Pharmaceutical Co., Ltd., West Virginia University

Conditions

GlaucomaOcular HypertensionOpen Angle Glaucoma or Ocular HypertensionOpen-angle Glaucoma

Phase 3

A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma

TerminatedNCT01426113

AllerganGlaucoma

Start: 2011-09-30End: 2014-10-31Updated: 2015-10-02

A Long-term Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With OAG or OH: RENGE Study

CompletedNCT02822729

Santen Pharmaceutical Co., Ltd.Open Angle Glaucoma or Ocular Hypertension

Start: 2016-07-01End: 2017-11-09Updated: 2017-11-20

Phase 4

African Glaucoma Laser Trial

WithdrawnNCT03648229

West Virginia UniversityOpen-angle Glaucoma

Start: 2019-09-01End: 2024-06-30Updated: 2021-06-21

Unknown Phase

Safety and Efficacy of Brimonidine Tartrate/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

CompletedNCT01229462

AllerganGlaucoma, Ocular Hypertension

Start: 2010-10-31End: 2011-09-30Updated: 2012-09-14

Related Papers

Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study.

2021-09-0828 citations